Single-Dose Oritavancin for ABSSSI – Phase 3 Trial Results | Dr. Ashwin Porwal
Clinical Study
Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections
📅 2014Published in New England Journal of Medicine
🕒 Approx. 3 min read | 👥 Dr. Ashwin Porwal, Healing Hands Clinic
AP
Dr. Ashwin Porwal
MS (Gen. Surgery) • Founder & Chief Surgeon, Healing Hands Clinic • India’s leading proctologist with 25+ years of clinical experience, 6 patents, and 60+ peer-reviewed publications. Pioneer of minimally invasive colorectal surgery in India.
📄 About This Publication
The SOLO I trial was a pivotal Phase 3 randomized controlled study comparing a single 1200 mg intravenous dose of oritavancin — a lipoglycopeptide antibiotic — versus twice-daily intravenous vancomycin for 7–10 days in adults with acute bacterial skin and skin structure infections (ABSSSIs).
The study enrolled patients with cellulitis, wound infections, or major cutaneous abscesses caused by gram-positive bacteria including MRSA (methicillin-resistant Staphylococcus aureus). The primary endpoint was a composite of cessation of lesion spread, absence of fever, and no rescue antibiotic use at 48–72 hours.
Single-dose oritavancin met the non-inferiority criteria, with clinical cure rates at 7–14 days statistically comparable to multi-day vancomycin therapy. The single-dose regimen dramatically simplifies treatment, potentially enabling outpatient care, reducing hospitalisation costs, and improving patient adherence — a landmark shift in ABSSSI management.
✓ Key Findings & Clinical Significance
✔ Single-dose IV oritavancin proven non-inferior to 7–10 days of vancomycin
✔ Active against MRSA and other gram-positive organisms
✔ Enables outpatient treatment of serious skin infections
✔ Published in New England Journal of Medicine — highest-impact medical journal
✔ Formed the basis for FDA approval of single-dose oritavancin (Orbactiv)
SOLO I proved that a single 1200 mg IV dose of oritavancin is as effective as 7–10 days of twice-daily IV vancomycin for serious acute bacterial skin infections.
Q: What bacteria does oritavancin cover?
Oritavancin is active against gram-positive bacteria including MRSA, MSSA, streptococci, and vancomycin-resistant enterococci (VRE).
Q: Why is single-dose oritavancin clinically significant?
It enables ABSSSI patients to receive complete treatment in one hospital visit, dramatically reducing inpatient costs and improving convenience compared to multi-day vancomycin infusions.
Healing Hands Clinic is India’s largest network of dedicated proctology and colorectal surgery centers, with 50+ locations across India and Dubai. Founded by Dr. Ashwin Porwal, the clinic specialises in minimally invasive treatments for piles, fissures, fistulas, rectal prolapse, constipation, and related colorectal conditions. NABH accredited, serving over 1 lakh patients annually since 2004.
Welcome to Healing Hands Clinic, where our expert team provides compassionate and specialized care in proctology. Our state-of-the-art facility ensures the highest standards of treatment and comfort for our patients. We prioritize your well-being and strive to make your experience as seamless and stress-free as possible. Trust Healing Hands Clinic for professional and personalized proctological care.
Disclaimer : The information on this site should not be considered as medical advice. Please consult a doctor for determining the best procedure as well as the most appropriate for your proctological needs.
